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Cancer cells in their respective microenvironments must endure various growth-constraining stresses.
Under these conditions, the cancer cell-derived factors are thought to modulate the signaling pathways between
cell growth and dormancy. Here, we describe a cancer cell-derived regulatory system that modulates the
phosphatidylinositol 3-kinase (PI3K)–Akt pathway under serum deprivation stress. Through the use of
biochemical puriﬁcation, we reveal that cancer cell-secreted insulin-like growth factor 1 (IGF-1) and clusterin,
an extracellular stress protein, constitute this regulatory system. We show that secreted clusterin associates
with IGF-1 and inhibits its binding to the IGF-1 receptor and hence negatively regulates the PI3K-Akt pathway
during serum deprivation. This inhibitory function of clusterin appears to prefer IGF-1, as it fails to exert any
effects on epidermal growth factor signaling. We demonstrate furthermore that the constitutive activation of
oncogenic signaling downstream of IGF-1 confers insensitivity to the inhibitory effects of clusterin. Thus, the
interplay between cancer cell-derived clusterin and IGF-1 may dictate the outcome of cell growth and dormancy
during tumorigenic progression.
The process of cell proliferation requires the integration of
various upstream signaling pathways. Physical contact with
neighboring cells (e.g., contact inhibition) and limitation to
environmental cues, such as growth factors, are key physiolog-
ical mechanisms that restrict normal cell growth. Oncogenic
transformation due to the accumulation of genetic lesions re-
sults in a loss of these properties, leading to uncontrolled cell
growth. However, during tumorigenic progression, cancer cells
continuously encounter various growth-constraining condi-
tions, such as hypoxia, acidosis, and nutritional deprivation (1,
15, 16, 33). Under these conditions, cancer cells must modulate
their signaling pathways to balance between cell growth and
dormancy (1, 40). The cellular mechanisms and genetic com-
ponents involved in this process are not clearly deﬁned. One
mechanism might be that cancer cell-derived factors support
their own growth and inﬂuence neighboring cells to induce a
favorable microenvironment (4, 6, 35, 36). A recent report that
cancer cells facilitate the expansion of highly proliferative stro-
mal ﬁbroblasts, which in turn promotes tumor progression,
supports this view (23). This ﬁnding highlights the importance
of cancer cell-derived paracrine factors in the initiation of
signaling events that eventually lead to a favorable environ-
ment for tumor growth. Identiﬁcation of these factors and
cognate signaling pathways is important to the interference of
the cross talk between cancer cells and the microenvironment.
Many signaling receptors, such as growth factor, cytokine,
and G protein-coupled receptors, rely on membrane-associ-
ated phosphatidylinositol-3,4,5-triphosphate (PIP3), a product
of phosphatidylinositol 3-kinase (PI3K), to elicit a wide vari-
ety of cellular responses (8, 13, 47). PI3K and its major down-
stream kinase, Akt, play key roles in many aspects of tumori-
genesis, such as cellular proliferation, survival, and migration
(2, 19). Constitutive activation of the PI3K-Akt pathway is
closely associated with cancer cell resistance to chemothera-
peutic agents. Deactivation of this pathway has been shown to
increase the efﬁcacy of many anticancer drugs, targeting a wide
range of cellular components (2, 19, 21). While the cellular
targets and processes elicited by the PI3K-Akt pathway are
well established, the mechanism by which cancer cells modu-
late this pathway in response to various growth-constraining
conditions is less deﬁned. Uncovering the regulatory systems
and genetic factors involved in this process will shed new light
on the mechanisms of chemoresistance and tumorigenic pro-
gression.
As a ﬁrst step to understanding the underlying cellular
events, we investigated the extracellular regulation of the
PI3K-Akt pathway in response to growth factor deprivation, a
physiologically relevant growth-constraining condition, using
HeLa cells as a model system for epithelial cancer cells. The
initial biochemical assay identiﬁed a cancer cell-derived regu-
latory activity. We clariﬁed the fact that this regulatory activity
consisted of both a positive activator(s) regulated by the PI3K-
Akt pathway itself and a negative factor(s). Using biochemical
puriﬁcation, we revealed that cancer cell-derived clusterin and
insulin-like growth factor 1 (IGF-1) constituted this regulatory
activity. By a combination of loss-of-function and gain-of-func-
tion studies, we demonstrated that clusterin negatively regu-
lated the PI3K-Akt pathway through the attenuation of IGF-1,
a major growth factor secreted by serum-starved cancer cells.
We showed that the activation of oncogenic signaling con-
* Corresponding author. Mailing address: Karp Family Research
Building, Room 10214, 1 Blackfan Circle, Boston, MA 02115. Phone:
(617) 919-2303. Fax: (617) 730-0885. E-mail: Hongbo.Luo@childrens
.harvard.edu.
† Supplemental material for this article may be found at http://mcb
.asm.org/.
 Published ahead of print on 5 May 2008.
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 ferred insensitivity to the inhibitory effects of clusterin. The
interplay between cancer cell-derived clusterin and IGF-1 may
provide a molecular framework with which to further dissect
the complex relationships between cancer cells and their envi-
ronments.
MATERIALS AND METHODS
Cell culture and stable cell lines. HEK293 and HeLa cells and their derivative
cell lines were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM).
NB4 cells were cultured in RPMI medium. For routine maintenance, all cell lines
were cultured in medium supplemented with 10% fetal bovine serum (FBS) and
1% penicillin and streptomycin under 5% CO2. Transfection was done using
Lipofectamine 2000 (Invitrogen) according to manufacturer’s guidance. To gen-
erate variant HeLa cells expressing a PIP3-binding pleckstrin homology (PH)
domain fused to enhanced green ﬂuorescence protein (PH-EGFP), the plasmid
containing PH-EGFP driven by a chicken beta-globin promoter was cotrans-
fected with pcDNA3.1 (Invitrogen). The transfected cells were selected for their
resistance to G418 (2 mg/ml) for 2 weeks, and the PH-EGFP-expressing clones
were isolated by using ﬂuorescence microscopy. For the HEK293 vector or
HEK293-Ras cells, HEK293 cells were transfected with the pBabe or pBabe-H-
Ras (V12) vector (26). The stable cell lines were selected and propagated in the
presence of puromycin (5 g/ml).
Reagents and antibodies. The human and zebraﬁsh clusterins in the pCMV-
SPORT6 vector were obtained from Openbiosystems. The clusterin short hairpin
RNA (shRNA) plasmids were purchased from Upstate (pKD-clusterin-v3) and
Openbiosystems (catalog no. RHS1764-9690776). Monoclonal clusterin antibody
(B-5; catalog no. sc-5289) and polyclonal clusterin antibody (H-330, catalog no.
sc-8354) were from Santa Cruz Biotechnology; alpha-actinin and actin antibodies
were from Sigma; phosphotyrosine antibody (catalog no. 4G10) was from Mil-
lipore; monoclonal IGF-1 (catalog no. CBL52) was from Chemicon Interna-
tional; IGF-1 receptor (catalog no. MAB391) antibody was fromR&DSystems;
horseradish peroxidase-conjugated anti-rabbit and anti-mouse secondary anti-
bodies were from Amersham Biosciences; all other antibodies were purchased
from Cell Signaling Technology. All chemicals, unless speciﬁed otherwise, were
obtained from Calbiochem.
Immunoblotting, immunodepletion, and immunoprecipitation. For the West-
ern blotting assay for adherent cells, cells were washed in phosphate-buffered
saline (PBS), and preheated 1 NuPAGE lithium dodecyl sulfate (LDS) buffer
(Invitrogen) was added directly to the plate (150 l per 35-mm dish). Lysates
were collected and boiled for 10 min in the presence or absence of -mercap-
toethanol. For cells grown in suspension, the cell pellet was made by centrifu-
gation and washed in PBS and resuspended in 50 l of PBS (per 1 million cells).
An equal volume of preheated 2 NuPAGE LDS buffer was added, and the
lysates were boiled. All protein samples were brieﬂy sonicated before they were
separated on NuPAGE 4 to 12% bis-Tris gels (Invitrogen). For conditioned
medium (CM), each sample was centrifuged for 15 min, and an aliquot of the
medium was mixed with 4 NuPAGE LDS buffer and boiled prior to electro-
phoresis. After electrophoresis, proteins were transferred onto polyvinylidene
diﬂuoride membranes (Millipore) that were blotted with the primary antibodies.
Except for the phospho-Akt (T308) antibody (5% bovine serum albumin in
Tris-buffered saline-Tween [TBS-T] buffer), all of the primary and the horserad-
ish peroxidase-conjugated secondary antibodies were incubated in 5% nonfat dry
milk (Bio-Rad) in TBS-T. The signal was detected using an ECL Plus Western
blotting detection system (Amersham). For immunodepletion, 10 l of 5 M NaCl
was added to 500 l of HeLa cell CM, and 5 g of monoclonal clusterin or
control antibody was added. After samples were incubated overnight at 4°C with
gentle rotation, 30 l of protein G/A-agarose slurry (Oncogene) was added, and
samples were incubated for3ha t4°C. After the mixtures were centrifuged, the
supernatants were checked for their abilities to activate Akt in NB4 cells. For
immunoprecipitation, HeLa cells grown overnight in 60-mm culture dishes were
serum starved for 30 min and then incubated with the intact or the heat-treated
CM (2 ml) for 20 min. Cells were washed in PBS and lysed in ice-cold lysis buffer
(10 mM Tris-HCl [pH 7.6], 1 mM EDTA, 150 mM NaCl, 1% NP-40) containing
cocktails of protease inhibitors (Roche) and protein phosphatase inhibitors
(Sigma). The lysates were cleared by centrifugation and incubated overnight with
2 g of EGF receptor or IGF-1  receptor. Twenty microliters of protein
G/A-agarose slurry was added and incubated for an additional 3 h. After samples
were washed three times with the lysis buffer at 4°C, the immunoprecipitates
were resolved on NuPAGE 4 to 12% bis-Tris gels and analyzed for the phos-
photyrosine level.
Biochemical puriﬁcation and protein identiﬁcation. HeLa cells grown over-
night in 100-mm dishes were washed once with PBS and incubated in 10 ml of
serum-free DMEM for 6 h. The medium was replaced with fresh serum-free
medium (10 ml per plate), and cells were incubated for another 36 to 48 h before
the collection step. A total of 1 liter of the CM was used for two independent
puriﬁcations. After centrifugation, the CM was loaded onto a column packed
with High Q (Bio-Rad) anion-exchange resin (10 ml of bed volume). The
ﬂowthrough fraction was loaded onto a butyl-S-Sepharose column (Amersham
Biosciences), the ﬂowthrough fraction was collected, and 0.1 N HCl was added
dropwise to adjust the pH to 4.5. The pH-adjusted sample was loaded onto a
High S (Bio-Rad) column (5 ml of bed volume) preequilibrated with acidic PBS
buffer (pH 4.5). The column was washed three times with acidic PBS buffer. The
bound activity was eluted (5 ml per fraction) by a pH gradient (5.0 to 8.0) in PBS
buffer. For the activity assay, 200 l of each fraction was diluted with an equal
volume of serum-free DMEM and heat treated at 65°C for 20 min. One million
preserum-starved NB4 cells were incubated in the heat-treated fractions for 30
min. After cells were centrifuged, the cell pellet was brieﬂy washed in PBS and
lysed directly by boiling in 1 LDS buffer. The active fractions were concen-
trated with a Centriprep 10K concentrator column (Amicon) and resolved on
NuPAGE 4 to 12% bis-Tris gels (Invitrogen). The protein bands of interest were
cut from the Coomassie-stained gel. In-gel digestion of gel bands, matrix-assisted
laser desorption ionization (MALDI) mass spectrometry analysis, and protein
identiﬁcation were done by the Taplin biological mass spectrometry facility at
Harvard Medical School.
Concentration of protein and removal of chemicals. Protein concentration was
done using Centriprep centrifugal ﬁlter devices (Amicon). The ﬁlter membrane
was rinsed twice in 15 ml of PBS by centrifugation for 30 min at 2,000  g.
Typically, 10 ml of CM was added to each device. The concentration process
(centrifugation and removal of ﬁltrate) was repeated until the volume of reten-
tate reached 1 ml. To remove the chemical inhibitors in the CM used in Fig. 2A,
the concentration process was repeated twice with serum-free medium.
Neutrophil isolation and transmigration assay. The isolation of mouse bone
marrow neutrophils and the transmigration assay were done essentially as de-
scribed previously (44).
MTT assay for cell proliferation. HEK293 cells (4  10
4 cells) were plated on
a 24-well plate in triplicate. Each well contained 250 l of 1% or 2.5% FBS
DMEM mixed with 250 l of the control or the clusterin-containing HEK293T-
CM. Cells were cultured for 3 days, and then 50 l of 5 mg/ml MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (dissolved in
PBS and ﬁltered through a 0.2-m nylon ﬁlter) was added to each well and
incubated at 37°C for 2 h. After the medium was removed, 900 l of isopropanol
with 0.1 M HCl was added to dissolve crystals. The solution was transferred into
1.5-ml Eppendorf tubes and centrifuged (14,000 rpm for 5 min). Absorbance of
the supernatant was measured at a wavelength of 570 nm, with background
subtraction at 650 nm.
Antibody neutralization and ELISA. All antibodies were diluted in PBS (0.1
mg/ml). For IGF-1 receptor neutralization, NB4 cells (1.0  10
6) grown over-
night in serum-rich medium were collected and washed once with PBS and
incubated in the presence of different amounts of antibodies in serum-free
medium (0.5 ml) for 30 min. Cells were collected and incubated with the heat-
treated HeLa cell-CM for 30 min. For IGF-1 neutralization, HeLa cell-CM was
heat treated and incubated with the control or IGF-1 antibody for1ha t4 ° Ca n d
then for 30 min at room temperature. Each CM sample was assayed in NB4 cells.
The enzyme-linked immunosorbent assay (ELISA) for IGF-1 was carried out
according to the manufacturer’s instructions (Quantikine, human IGF-1;R&D
Systems). To determine the IGF-1 level in HeLa cell-CM, the intact or heat-
treated CM (100 l) collected at different time points was analyzed along with
the serially diluted IGF-1 standard. For the recovery of IGF-1, puriﬁed IGF-1 (2
ng) was incubated with the control or clusterin-containing HEK293T cell-CM
(100 l) for 1 h on ice, and then the amount of IGF-1 was determined by ELISA.
IGF-1 binding and pull-down experiments. The human and zebraﬁsh clusterin
clones in the pCMV-SPORT6 vector were subcloned into the pcDNA3.1/TOPO-
V5-HIS vector (Invitrogen) by PCR. The plasmid was transfected into HEK293T
cells, and serum-free CM was collected. CM was incubated with puriﬁed IGF-1
(200 ng/ml) for1ho nice, and then Ni-nitrilotriacetic acid (NTA)-agarose beads
(Qiagen) were added (50 l/ml CM), and the solution was incubated overnight
in a cold room with gentle rotation. The beads were then washed three times in
PBS with imidazole (20 mM). After the ﬁnal wash in PBS, the beads were boiled
in 1 LDS buffer without a reducing agent and analyzed for IGF-1 by Western
blotting. For IGF-1 coimmunoprecipitation and ELISA detection, HEK293 cells
(5  10
6) were serum starved for 24 h and washed once with ice-cold PBS and
then stimulated for 5 min at room temperature with the control or the clusterin-
containing CM that had been preincubated with IGF-1 (50 ng/ml) on ice for 1 h.
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 The cells were washed once with ice-cold PBS and lysed for 30 min on ice in the
lysis buffer {40 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.3%
CHAPS [3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate] with
protease inhibitor cocktails }. The cells were collected in a tube and sonicated
brieﬂy before debris was cleared by centrifugation. The cleared lysates were
preincubated with the rabbit control or the IGF-1  receptor antibody (10 g/ml
of lysate) for 1 h, and then protein A/G beads were added, and the samples were
incubated overnight with gentle rotation. The immune complex was washed three
times with ice-cold PBS and resuspended in 100 l of PBS. The immune complex
was heat treated at 75°C for 30 min and then analyzed for the presence of IGF-1
by ELISA.
RESULTS
Serum-starved HeLa cells secrete an Akt-activating activity.
A number of signaling receptors rely on the PI3K-Akt pathway
to control a wide range of cellular responses. However, how
this pathway is regulated under cellular stress conditions is not
well deﬁned. We hypothesized that cancer cells under growth
constraint conditions secrete soluble factors to modulate the
PI3K-Akt pathway. To identify such regulatory factors, we
established a biochemical system. We chose serum starvation
as one of the paradigms for cellular stress. It is known that
cellular stresses caused by serum deprivation cross talk with
hypoxic responses (3, 11, 51), analogous to that in in vivo
cancer cells. Also, excluding other serum factors allowed us to
identify the cancer cell-derived signaling modulators.
Akt is recruited onto the plasma membrane through its
speciﬁc binding to PIP3, a product of PI3K, and is activated by
phosphorylation; thus, Akt phosphorylation has been used
widely as an indicator of PI3K-Akt pathway activation (8, 9, 32,
39, 46). HeLa cells grown in serum-rich medium were replen-
ished with serum-free medium, and the level of phospho-Akt
was examined at the indicated time points. Interestingly, the
proﬁle of the phospho-Akt exhibited a biphasic nature, that is,
the lowest level appeared at ﬁrst, followed by a gradual in-
crease, and moderate levels were sustained at later time points
(Fig. 1A). While the kinetics and levels of reactivation were
slightly variable between experiments, the biphasic nature of
phospho-Akt was highly reproducible (Fig. 1A and see Fig.
S1A in the supplemental material). The initial deactivation
(dephosphorylation) of Akt was rapid and came about within
one-half hour of serum removal (see Fig. S1B in the supple-
mental material). The presence of growth factors, such as IGF,
completely prevented this initial deactivation (Fig. 1B). Under
the identical conditions, the initial deactivation of phospho-
Erk was not obvious, and its response to IGF was much less
robust than that of phospho-Akt (Fig. 1A and B and see Fig.
S1A in the supplemental material).
The reactivation of Akt following the initial deactivation
could be due to restimulation by an extracellular Akt activa-
tor(s) secreted by the starved HeLa cells. If this is the case, the
serum-free culture medium in which HeLa cells were grown
(the CM) should contain the Akt-activating activity. To test
this possibility, the serum-free CM from HeLa cells was col-
lected at 12-h intervals for 3 days, and the ability to activate
Akt (i.e., to prevent the initial deactivation upon serum re-
moval) was examined in a new batch of cells. The serum-free
CM, indeed, contained the Akt-activating activity. This activity
was increased up until 36 h, followed by a gradual decrease,
leading to an almost complete lack of activity by 72 h (Fig. 1C).
To better understand the molecular nature of the secreted
Akt-activating activity, we ﬁrst determined its physical proper-
ties. Interestingly, the preheating treatment at 65°C signiﬁ-
cantly enhanced the Akt-activating activity, while it had no
effect on the level of phospho-Erk (Fig. 1D). To assess the
molecular weight, we applied the CM to a ﬁltration membrane
designed to separate macromolecules based on their size. The
activity was found to be bigger than 50 kDa, even after the
preheating treatment (see Fig. S1C and S1D in the supplemen-
tal material). The activation of Akt by either the heat-treated
or the untreated CM was blocked in the presence of Akt or
PI3K inhibitor, suggesting that this activity acts upstream of
PI3K (Fig. 1E).
The PI3K-Akt signaling pathway mediates the secretion of
Akt-activating activity. The expression of signaling ligands and
antagonists is often under the control of their cognate signaling
pathways. To determine if the level of Akt-activating activity in
HeLa-CM could be regulated by the PI3K-Akt pathway, we
treated HeLa cells with a sublethal amount of PI3K or an Akt
inhibitor. Residual chemicals from the CM were removed by
ﬁltration (see Materials and Methods), and their absence from
the CM was conﬁrmed (Fig. 2A). Each CM sample was then
tested for Akt-activating activity. Compared with the control
CM, the drug-treated CM showed a signiﬁcantly reduced ac-
tivity level (Fig. 2B). To substantiate this ﬁnding, we generated
variant HeLa cells with compromised PI3K signaling. The el-
evation of PIP3, a product of PI3K, and its recognition by
various cellular proteins are the key steps for the PI3K-elicited
cellular processes. We reasoned that the ectopic expression of
the PIP3-binding PH domain would sequester the endogenous
PIP3, hence attenuating the PI3K signaling. We generated two
independent stable HeLa cell lines expressing a PH domain of
Akt fused to EGFP, HeLa-PH1 and HeLa-PH2. As expected,
compared to the wild-type HeLa cells, the HeLa-PH cells
showed a reduced basal level of phospho-Akt (Fig. 2C). When
the CM from the variant HeLa cells was tested for secreted
Akt-activating activity, the variant CM, unlike wild-type HeLa-
CM, showed no activity (for HeLa-PH1) or a much reduced
activity (for HeLa-PH2) level at all time points (Fig. 2D). The
lack of Akt-activating activity in the CM from HeLa-PH cells
(HeLa-PH-CM) was indeed due to its inability to activate the
PI3K, as it failed to induce the membrane translocation of
PH-EGFP, a process mediated by PIP3 (Fig. 2E). Together
with the previous results using chemical inhibitors, these ﬁnd-
ings suggest that the secretion and/or synthesis of Akt-activat-
ing activity is mediated by the PI3K-Akt signaling pathway.
Serum-starved HeLa cells also secrete a negative regulator
of PI3K-Akt pathway. Heat activation is a unique feature of the
HeLa cell-secreted PI3K-Akt-activating activity. We found
that a preheating treatment of puriﬁed growth factors, such as
IGF, had no differential effect (Fig. 3A). One mechanism that
may explain this ﬁnding is the presence of a heat-sensitive
negative regulator. The heat treatment may lead to conforma-
tional changes of this regulator and thus suppress its inhibitory
effect on Akt activation. Supporting this idea, the CM from
HeLa-PH cells, which do not secrete the Akt-activating activ-
ity, further decreased the basal level of phospho-Akt under
serum-free conditions. The preheating treatment of CM from
HeLa-PH cells abolished this inhibitory effect (Fig. 3A). Con-
sistent with this ﬁnding, the concentrated CM from HeLa-PH
cells reduced the level of phospho-Akt in HeLa cells, even
VOL. 28, 2008 CLUSTERIN AS A REGULATOR OF THE PI3K-AKT PATHWAY 4287
 
a
t
 
H
a
r
v
a
r
d
 
L
i
b
r
a
r
i
e
s
 
o
n
 
J
u
l
y
 
2
4
,
 
2
0
0
8
 
m
c
b
.
a
s
m
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 under serum-rich conditions (Fig. 3B). The PI3K-Akt-activat-
ing activity in the CM from wild-type HeLa cells was reduced
at later time points (72 h) (Fig. 1C). The preheating treatment
of this CM signiﬁcantly recovered the Akt-activating activity
(Fig. 3C), further indicating the presence of a heat-sensitive
negative regulator.
Biochemical puriﬁcation identiﬁes clusterin as a protein
associated with the PI3K-Akt-activating activity. We found
that the enhancement of Akt-activating activity by heat treat-
ment was retained after pretreating CM under high-salt, re-
ducing, and both basic and acidic conditions (data not shown),
indicating that the negative and positive regulators may exist in
a complex. Therefore, we decided to biochemically purify them
by following the Akt-activating activity. We have found that
several other cancer cell types could also respond to the
secreted Akt-activating activity from HeLa-CM (data not
shown). For this biochemical puriﬁcation, we utilized NB4 cells
(an acute promyelocytic leukemic cell line) to measure the
Akt-activating activity. NB4 cells were cultured in suspension;
therefore, the contribution of Akt regulation by the cell adhe-
sion-related processes was minimized. In addition, unlike
HeLa cells, very little reactivation of basal phospho-Akt was
FIG. 1. Serum-starved HeLa cells secrete an Akt-activating activity. (A) HeLa cells grown in serum-rich medium (10% FBS in DMEM)
overnight were replenished with serum-free medium, and the phospho-Akt (S473) and phospho-Erk (Thr202/Tyr204) from the whole-cell lysates
were examined at the indicated time points. (B) HeLa cells grown overnight in serum-rich medium were replenished with serum-free medium or
serum-free medium with the indicated amount of IGF-1 for 20 min. The whole-cell lysates were analyzed for phospho-Akt and phospho-Erk.
(C) The CM from serum-starved HeLa cells was collected every 12 h. Each CM sample was added to a new batch of HeLa cells that had been
serum deprived for 30 min. After cells were incubated for 30 min, the ability of each CM to increase the level of phospho-Akt activity was
determined. (D) The serum-free HeLa cell CM (36 h) was heat treated at 65°C for the indicated times, and cooled to room temperature for 30
min. The Akt-activating activity of heat-treated CM was analyzed as described in the legend to panel C. (E) The Akt-activating activity of untreated
or heat-treated HeLa cell CM was determined in the presence of the indicated amounts of LY294002 or Akt inhibitor (7.2 M).
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 found in NB4 cells during serum deprivation, making the back-
ground level consistently very low in each assay. To trace the
Akt-activating activity level that can be enhanced by heat treat-
ment, each fraction was treated at 65°C for 20 min and tested
for its ability to increase the phospho-Akt level in serum-
starved NB4 cells (see methods in the supplemental material).
We showed that the Akt-activating activity existed in the
ﬂowthrough fractions of the hydrophobic (butyl-S-Sepharose)
and anion-exchange columns (High Q). This activity could be
retained on the cation-exchange (High S) column and recov-
ered by elution with a pH gradient (see Fig. S2A, B, and C in
the supplemental material). We then attempted to identify the
proteins from this intermediate puriﬁcation by mass spectrom-
etry analysis.
The ﬁnal fractions from two independent puriﬁcations were
tested for Akt-activating activity. Consistent with the previous
observation that this activity acts upstream of the PI3K path-
way (Fig. 1E and 2E), phosphorylation of both Akt-T308 and
Akt-S473 was enhanced by the puriﬁed activity (Fig. 4A). Us-
ing the Coomassie staining of these fractions, we identiﬁed
eight bands that appeared to be correlated with the activity
(Fig. 4B, enriched in the E1-P and E2-fraction 11 but not in the
E2 fractions 9 and 10; see also Fig. S2C in the supplemental
material), and these were subjected to MALDI analysis. In-
FIG. 2. The PI3K-Akt signaling pathway mediates the secretion of Akt-activating activity. (A) HeLa cells were cultured in serum-free medium
for 24 h in the presence of dimethyl sulfoxide (DMSO), LY294002 (5 M), wortmannin (WM, 0.1 M), or Akt inhibitor (3.6 M). The CM was
ﬁltered through a Centriprep-10K column to remove the residual chemicals (see Materials and Methods). The ﬁltered CM was mixed with IGF-1
(1 ng/ml) and tested for the removal of residual drug. (B) Each CM sample from the experiment described in the legend to panel A was untreated
or heat treated, and its ability to activate Akt was assayed in HeLa cells. (C) The whole-cell lysates of HeLa cells or HeLa-PH cells grown in
serum-rich medium were analyzed for phospho-Akt level. (D) The serum-free CM from HeLa, HeLa-PH1, or HeLa-PH2 cells was collected at
12-h intervals and tested for its ability to activate Akt. (E) The CM from HeLa or HeLa-PH cells was added to HeLa-PH cells that had been serum
starved for 12 h. After the HeLa-PH cells were incubated for 30 min, they were ﬁxed in 3% paraformaldehyde, and the membrane translocation
of PH-EGFP was examined using ﬂuorescence microscopy (20 objective). Arrows indicate the membrane translocation of PH-EGFP.
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 triguingly, one of the proteins identiﬁed, clusterin, was de-
tected in all eight samples, with a high percentage of peptide
coverage (Fig. 4C). The Western blotting analysis conﬁrmed a
broad range of clusterin immunoreactivity that corresponded
to the analyzed bands (Fig. 4D).
Clusterin is a multifunctional protein involved in various
biological processes, including tumorigenesis (17, 41), al-
though the underlying mechanisms are still poorly charac-
terized. Its function as an extracellular chaperon and its
regulation by cellular stresses prompted us to evaluate this
protein further. First, we found that clusterin was accumu-
lated in the CM during serum starvation (Fig. 4E). Since the
Akt-activating activity in CM can be enhanced by heat treat-
ment, we determined if heat treatment could affect the
conformation of clusterin. The heat treatment led to a high-
molecular-weight complex of clusterin, indicating a struc-
tural change(s) (Fig. 4F). Longer periods of treatment at a
higher temperature (80°C over 3 h) led to its degradation in
a manner corresponding to the loss of Akt-activating activity
(Fig. 4F). When the High S-bound activity was subjected to
elution by a ﬁne gradient of pH, clusterin was coeluted with
the Akt-activating activity (see Fig. S2D in the supplemental
material). In addition, the immunodepletion of clusterin
from the CM led to a reduced Akt-phosphorylating activity,
indicating that clusterin is associated with the Akt-activating
activity (Fig. 4G).
Clusterin is a secreted negative regulator of the PI3K-Akt
signaling pathway. We showed that serum-starved HeLa cells
secrete both positive and negative regulators of the PI3K-Akt
pathway (Fig. 3). Clusterin is associated with the Akt-activating
activity, but whether it acts as a positive or a negative regulator
needs to be determined. First, we took advantage of those
HeLa-PH cells whose CM lacked the Akt-activating activity
(Fig. 2C and D). Equal amounts of CM from wild-type HeLa
(HeLa-CM) and HeLa-PH-CM were subjected to the High S
column, and bound proteins were eluted by a pH gradient. The
level of clusterin in each fraction of HeLa-PH-CM was not
different from that of corresponding fractions of HeLa-CM.
FIG. 3. Serum-starved HeLa cells also secrete a negative regulator of the PI3K-Akt pathway. (A) Serum-free medium, IGF-1, or CM from
HeLa or HeLa-PH cells was untreated or heat treated, and their abilities to activate Akt were tested. (B) The CM from HeLa-PH or its column
fraction was added to HeLa cells grown in serum-rich medium (20% volume of the medium) and incubated for 30 min prior to analysis for
phospho-Akt. For the Centriprep column retentate (RT), the CM was concentrated with the Centriprep 10K or 50K ﬁlter column. Each
concentrate (10) was added directly to HeLa cells grown in serum-rich medium. (C) The HeLa cell CM collected after 48 h or 72 h of serum
starvation was untreated or heat treated, and its ability to activate Akt was assayed.
4290 JO ET AL. MOL.C ELL.B IOL.
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 FIG. 4. Biochemical puriﬁcation identiﬁed clusterin as a protein associated with the PI3K-Akt-activating activity. (A) The active fractions eluted from
the High S column from two independent puriﬁcation experiments (see Fig. S3 in the supplemental material) were mixed (1:1) with serum-free
medium. After heat treatment, their ability to phosphorylate S473 and T308 of Akt was assayed in NB4 cells. Exp1 and Exp2 indicate two
independent puriﬁcation experiments. P indicates the pooled activity from the ﬁrst puriﬁcation. NS indicates a nonspeciﬁc band. (B) The
corresponding fractions were concentrated with a Centriprep 10K column. Proteins were resolved on a NuPAGE 4 to 12% gel stained with
Coomassie blue. Arrows indicate the protein bands analyzed by MALDI mass spectrometry. (C) Human clusterin peptides identiﬁed by MALDI
analysis are underlined. (D) Western blotting (WB) of the corresponding fractions, using C-terminal-speciﬁc monoclonal clusterin antibody.
(E) Serum-free CM from HeLa cells collected at the indicated time points was analyzed for clusterin. (F) CM from HeLa cells was heat treated
for the indicated times, and proteins were analyzed with the C-terminal-speciﬁc clusterin antibody. The bracket indicates the high-molecular-weight
complexes induced by heat treatment (top). Akt-activating activity of the corresponding CM was tested in NB4 cells (bottom). (G) CM was
immunodepleted with the protein G/A beads alone (control), the control antibody (monoclonal anti-GSK), or the C-terminal-speciﬁc clusterin
antibody. The supernatant was analyzed for clusterin (at left). Their abilities to activate Akt were tested in NB4 cells (at right).
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 However, all fractions from HeLa-PH-CM lacked the Akt-
activating activity when they were tested in NB4 cells (Fig. 5A),
indicating that clusterin by itself does not function as an Akt-
activating factor.
Previously, we observed that concentrated HeLa-PH-CM
inhibited Akt phosphorylation (Fig. 3B). Therefore, we exam-
ined whether HeLa-PH-CM could inhibit the Akt-activating
activity present in HeLa-CM. In the presence of equal amounts
of HeLa-PH-CM, Akt phosphorylation by HeLa-CM was
strongly inhibited, and, moreover, HeLa-PH-CM fractions
from the High S column also reduced Akt phosphorylation in
a manner that correlated with its clusterin level (Fig. 5B). This
ﬁnding indicates the possibility that clusterin may play an in-
hibitory function. If this is the case, then the reduction of
clusterin in HeLa-PH-CM should attenuate its ability to inhibit
HeLa-CM-mediated Akt activation. To test this possibility, we
knocked down the endogenous clusterin in HeLa-PH cells by
RNA interference (Fig. 5C), and then the CM from these cells
was tested for its ability to inhibit the Akt phosphorylation by
HeLa-CM. We found that a signiﬁcant reduction of clusterin in
HeLa-PH cells, in which prosurvival IGF-1 signaling was com-
promised, led to apoptosis under serum-deprived conditions
(see Fig. S7 in the supplemental material). Thus, we relied on
a moderate knockdown that did not cause apoptosis. Com-
pared to CM from empty vector- or control shRNA-expressing
HeLa-PH cells, the CM from the clusterin-shRNA-expressing
HeLa-PH cells manifested a reduced inhibitory activity when
tested in both the NB4 (Fig. 5D) and the HEK293 cells (Fig.
5E), strongly indicating a negative role for clusterin.
We then asked if the ectopic expression of clusterin could
confer a similar inhibitory activity in a heterologous system.
For this end, we used HEK293T cells, which almost completely
lack endogenous clusterin and do not secrete Akt-activating
factors during serum starvation (Fig. 6A). We transfected
HEK293T cells with the empty or clusterin-expressing (Clu)
vector, and the serum-free CM was collected. Neither the
vector control nor clusterin-containing HEK293T-CM showed
any effects on the Akt phosphorylation when tested with NB4
cells (Fig. 6A). However, compared with the control CM, the
CM from clusterin-transfected cells (HEK293T-Clu) markedly
inhibited the Akt phosphorylation induced by HeLa-CM when
tested with both NB4 cells and HeLa cells (Fig. 6B and C).
Activation of the PI3K-Akt pathway promotes cell prolif-
eration (31, 42). To determine if clusterin could exert a
sustained inhibitory effect on the PI3K-Akt pathway, we
examined its effects on cell proliferation. The same number
FIG. 5. Clusterin is a secreted negative regulator of the PI3K-Akt signaling pathway. (A) The High S column-bound proteins from HeLa cell
CM (HeLa-CM) or HeLa-PH cells (HeLa-PH-CM) were eluted by the pH gradient. The eluted fractions were analyzed for clusterin (top), and
the corresponding fractions were tested for their ability to activate Akt in NB4 cells (bottom). (B) HeLa-PH-CM inhibits the Akt activation elicited
by HeLa-CM. HeLa-PH-CM and its fractions shown in panel A were mixed (1:1) with HeLa-CM and tested for their abilities to inhibit
HeLa-CM-elicited Akt activation in NB4 cells. (C) The shRNA-mediated knockdown of clusterin in HeLa-PH1 cells is shown. HeLa-PH1 cells
were transfected with the empty vector, the control shRNA vector, or two different clusterin shRNA vectors, and then the serum-free CM (24 h)
and the whole-cell lysates of each transfectant were analyzed for clusterin expression. (D and E) Each HeLa-PH-CM was mixed (1:1) with
HeLa-CM and tested as described in the legend to panel B for the ability to inhibit HeLa-CM-mediated Akt phosphorylation in NB4 or HEK293
cells. The representative Western blotting of at least three independent experiments is shown.
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 of HEK293 cells were plated using the reduced serum con-
ditions (1% and 2.5%) in the presence of control or clus-
terin-containing HEK293T-CM and cultured for 3 days. As
revealed by the relative cell proliferation, compared to that
of the control, the presence of clusterin led to a 28 to 30%
reduction in cell proliferation (Fig. 6D). Taken together,
these data support a role for clusterin in the negative reg-
ulation of the PI3K-Akt pathway.
Clusterin inhibits the IGF-1- but not the EGF-mediated
signaling pathway. Next, we decided to identify the Akt acti-
vator(s) that is inhibited by clusterin. First, we found that the
heat-treated HeLa-CM did not enhance G protein-coupled
receptor signaling as determined by Akt activation and che-
motactic migration of mouse peripheral neutrophils (see Fig.
S3A and B in the supplemental material). We then checked for
the growth factor receptor signaling. NB4 cells lack both the
PDGF and the EGF receptors (data not shown). This ﬁnding
led us to examine IGF receptor signaling. Using a phosphory-
lation-speciﬁc antibody, we determined the kinetics of IGF-1
receptor activation by HeLa-CM with or without heat treat-
ment. HeLa-CM activated the IGF-1 receptor, and its activa-
tion preceded that of Akt phosphorylation. Importantly, the
heat treatment of HeLa-CM signiﬁcantly enhanced the activa-
tion of the IGF receptor (Fig. 7A). Next, we asked if the
activation of the IGF receptor by HeLa-CM was responsible
for Akt activation. For this purpose, we took advantage of a
neutralizing antibody against the IGF-1 receptor (27). Prein-
cubation of NB4 cells with the IGF-1 receptor-neutralizing
antibody, but not the control antibody, markedly inhibited the
Akt activation by the heat-treated HeLa-CM (Fig. 7B). Acti-
vation of the IGF-1 receptor strongly indicates the presence of
its ligands, such as IGF-1, in HeLa-CM. However, its activation
could be also due to cross talk between signaling receptors (12,
25). Therefore, we determined if similar neutralization of
IGF-1 could affect the Akt-activating activity of HeLa-CM.
The inhibitory activity of the IGF-1-neutralizing antibody has
been well documented (34). We also conﬁrmed that this anti-
body blocked the activity of both puriﬁed and serum IGF-1
(see Fig. S3C in the supplemental material). The IGF-1-neu-
tralizing antibody, but not the control antibody, almost com-
pletely abolished Akt activation by heat-treated HeLa-CM
(Fig. 7C). Next, we determined if IGF-1 was indeed secreted by
HeLa cells during serum starvation. We showed that serum-
free CM from HeLa-PH cells lacked Akt-activating activity
(Fig. 2D). Therefore, we measured the amount of IGF-1 in
HeLa-CM and HeLa-PH-CM with or without heat treatment,
by ELISA. The results showed that IGF-1 was indeed present
in HeLa-CM and its level peaked at 36 h and decreased there-
after. Importantly, the heat treatment signiﬁcantly increased
the detectable level of IGF-1, and the amount of IGF-1 de-
tected in 72-h HeLa-CM was comparable (slightly higher) to
that detected in 36-h HeLa-CM (Fig. 7D). As expected, very
little IGF-1 was detected in untreated and heat-treated HeLa-
PH-CM (Fig. 7D), conﬁrming that the lack of IGF-1 was
responsible for its inability to activate Akt.
We showed that ectopic clusterin inhibited the Akt-activat-
ing activity of HeLa-CM (Fig. 6B and C), indicating that clus-
terin may attenuate IGF-1 function. To test this possibility, we
preincubated the puriﬁed IGF-1 with the control or the clus-
terin-containing HEK293T-CM and then compared their ac-
tivity levels. Consistent with our prediction, the presence of
clusterin led to a functional inhibition of IGF-1, as revealed by
a decreased activation of the IGF-1 receptor and Akt (Fig. 7E).
To further determine if the inhibitory function of secreted
FIG. 6. Ectopic expression of clusterin inhibits PI3K-Akt activation and cell proliferation. (A) The empty control (Con) vector or the
clusterin-expressing plasmid (Clu) was transfected into HEK293T cells. The resulting serum-free CM (30 h) fractions were analyzed for clusterin
expression (left) and their abilities to affect the Akt phosphorylation in NB4 cells (right). (B) The Con- or Clu-containing HEK293T-CM samples
were mixed (1:1) with HeLa-CM and left untreated or were heat treated and tested for their abilities to affect HeLa-CM-mediated Akt
phosphorylation in NB4 cells. (C) Effects of clusterin on HeLa-CM-elicited Akt phosphorylation in HEK293 cells. (D) The Con- or Clu-containing
HEK293T-CM was mixed (1:1) with different amounts of serum and added to HEK293 cells in triplicate. Cell proliferation was measured by MTT
assay after 72 h. Results are the means  standard errors of three independent experiments.
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 clusterin is preferential for IGF-1 or if it functions generally to
inhibit other growth factors, we examined its effects on EGF
signaling.
We found that the preheating treatment of HeLa-CM failed
to enhance the activity of the EGF receptor, while it markedly
increased that of the IGF-1 receptor (see Fig. S3D in the
supplemental material). Next, we determined if clusterin could
affect the activity of puriﬁed EGF. Within 5 min, the stimula-
tion of starved HeLa cells with EGF led to a robust activation
of the EGF receptor, Akt, and Erk (see Fig. S3E in the sup-
FIG. 7. Clusterin inhibits the IGF-1-mediated, but not the EGF-mediated, signaling pathway. (A) Serum-starved NB4 cells were incubated with
the untreated [heat()] or heat-treated [heat()] HeLa-CM for the indicated times, and the activation of the IGF-1 receptor and Akt was analyzed
in whole-cell lysates. (B) NB4 cells were preincubated with different amounts of control or IGF-1 receptor-neutralizing antibody in serum-free
medium and then incubated with heat-treated HeLa-CM for 30 min before the HeLa-CM was analyzed for phospho-Akt level. (C) The
IGF-1-neutralizing antibody blocked the HeLa-CM-elicited Akt activation. The heat-treated HeLa-CM was preincubated with the control or
IGF-1-neutralizing antibody, and then the ability to activate Akt was tested in NB4 cells. (D) Secretion of IGF-1 by serum-starved HeLa cells. The
levels of IGF-1 in untreated or heat-treated CM collected from HeLa cells or HeLa-PH cells at different time points of serum starvation were
measured by ELISA. (E) Functional inhibition of IGF-1 by clusterin. The puriﬁed IGF-1 was preincubated with the control (HEK293T-Con-CM)
or clusterin-containing CM (HEK293T-Clu-CM) and assayed for the activation of IGF-1 receptor and Akt in NB4 cells. (F) The puriﬁed EGF (5
ng/ml) was preincubated with the control or clusterin-containing CM as described in the legend to panel E and assayed for the activation of the
EGF receptor, Akt, and Erk in serum-starved HeLa cells at the indicated time points.
4294 JO ET AL. MOL.C ELL.B IOL.
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 plemental material). Unlike clusterin’s inhibitory function to-
ward IGF-1 (Fig. 7E and Fig. 8A), at all time points, the
presence of clusterin had little effect on the activation of the
EGF receptor and its downstream components (Fig. 7F).
Clusterin associates with IGF-1 and inhibits its binding to
the IGF-1 receptor. To gain insight into the mechanism by
which clusterin attenuates IGF-1 function, we ﬁrst determined
its effects on the kinetics of IGF-1-induced Akt activation in
NB4 cells. Upon IGF-1 stimulation, the phosphorylation of
IGF-1 receptor peaked at 5 min, gradually decreased over the
next 40 min, and then increased over the next 15 min. The later
increase (at 60 min) could be due to an elevation of the IGF-1
receptor itself. The level of pAkt gradually increased for 20
min and remained the same thereafter. The presence of clus-
terin markedly inhibited the activation of both the IGF-1 re-
ceptor and Akt at all time points, indicating that it directly
attenuates IGF-1 function rather than perturbs its signaling
kinetics (Fig. 8A). The level of phospho-Erk was also reduced
in the presence of clusterin, although not as signiﬁcantly as that
of phospho-Akt. The levels of downstream IGF-1 signaling
components, such as IRS-1, p85, and PTEN, of the control
were not noticeably different than those of the clusterin-con-
taining CM (Fig. 8A).
Clusterin was copuriﬁed with the Akt-activating activity,
which contains IGF-1 (Fig. 4 and see Fig. S2E in the supple-
mental material), suggesting that they may exist in a complex.
FIG. 8. Clusterin associates with IGF-1 and inhibits its binding to the IGF-1 receptor. (A) The time course analysis of IGF-1-induced Akt
activation in the presence or absence of clusterin. The puriﬁed IGF-1 (2 ng/ml) was preincubated with the control (Con) or clusterin-containing
(Clu) CM and treated in NB4 cells for the indicated times and assayed for the IGF-1 signaling components. (B) The puriﬁed IGF-1 was treated
as described in the legend to panel A, and the amount was determined by ELISA. (C) The HEK293T-CM collected after transfection with the
control or the C-terminal His6-tagged human or zebraﬁsh (zﬁsh) clusterin vector was preincubated with puriﬁed IGF-1 and pulled down with
Ni-NTA agarose beads and analyzed for IGF-1. (D) Serum-starved HEK293 cells were stimulated; puriﬁed IGF-1 was treated as described in the
legend to panel A and then immunoprecipitated with IGF-1b receptor. The immune complex was analyzed for IGF-1 by ELISA.
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 To determine if clusterin could form a complex with IGF-1 in
vitro, we employed two independent approaches. First, we
incubated the puriﬁed IGF-1 with the control or the clusterin-
containing CM and determined if clusterin could affect the
accessibility of IGF-1. We found that preincubation with clus-
terin reduced the amount of IGF-1 detected by ELISA (Fig.
8B). Next, we performed a biochemical pull-down experiment.
We found that, under a nonreducing condition, the puriﬁed
IGF-1 could be readily detected by Western blotting (see Fig.
S4A in the supplemental material). For the pull-down experi-
ment, the C-terminally tagged (V5 and His6) clusterin was
expressed in HEK293T cells. As a control, we used the ze-
braﬁsh clusterin, which shares less than 40% identity with
human clusterin but is readily glycosylated and secreted when
expressed in HEK293T cells (see Fig. S4B and C in the sup-
plemental material). The puriﬁed IGF-1 was incubated with
the control or the human clusterin- or the zebraﬁsh clusterin-
containing CM and pulled down with Ni-NTA beads. This
experiment revealed that the puriﬁed human IGF-1 could form
a complex with human clusterin but not with zebraﬁsh clusterin
(Fig. 9C). Next, we determined if clusterin prevents binding of
IGF-1 to its receptor. For this end, serum-starved HEK293
cells were stimulated with IGF-1 that had been preincubated
with control or clusterin-containing CM and then immunopre-
cipitated with the nonneutralizing IGF-1 receptor antibody.
Given the fact that the puriﬁed IGF-1 is heat stable (Fig. 3A),
we heat treated the immunocomplex to release the bound
IGF-1, and its level was measured by ELISA. Consistent with
the previous results, the presence of clusterin reduced the
amount of IGF-1 bound to its receptor (Fig. 8D). Together,
these results suggest that clusterin attenuates IGF-1 signaling
by interfering with its binding to the receptor.
Oncogenic signaling leads to insensitivity to clusterin-me-
diated inhibition. Our data show that clusterin plays negative
roles in the PI3K-Akt pathway through the inhibition of IGF-1
function. If this is the primary mechanism, then constitutive
FIG. 9. Oncogenic signaling leads to insensitivity to clusterin-mediated inhibition. (A and B) The control (Con)- or clusterin (Clu)-containing
HEK293T-CM was mixed with HeLa-CM (1:1), and samples were tested for their abilities to affect Akt phosphorylation in HEK293 and HEK293T
cells. (C) The Con- or Clu-containing HEK293T-CM was mixed with HeLa-CM in the presence of the indicated amounts of LY294002 and then
tested for their effects on Akt phosphorylation in HEK293T cells. (D) The Con- or Clu-containing HEK293T-CM was mixed (1:1) with HeLa-CM
and tested for the ability to affect HeLa-CM-mediated Akt phosphorylation in HEK293-Ras or HEK293-vector cells. (E) Whole-cell lysates of
serum-starved HeLa, HEK293, HEK293T, or HEK-Ras and their corresponding CM fractions were tested for Akt-activating activity in NB4 cells.
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 activation of downstream components of IGF-1 receptor should
confer insensitivity to clusterin. To investigate this possibility,
we examined the effects of clusterin on cell lines containing the
impaired IGF-1 receptor signaling. Consistent with previous
reports (14, 38), we found that compared to the level of PI3K
activation found with wild-type HEK293 cells, HEK293T cells
in which simian virus 40 large T (SV40T) antigen is overex-
pressed had a high level of PI3K activation, as demonstrated by
a prominent augmentation of PIP3-mediated membrane trans-
location of PH-EGFP (see Fig. S5A in the supplemental ma-
terial). Unlike that in wild-type HEK293 cells, clusterin failed
to affect Akt phosphorylation in HEK293T cells (Fig. 9A and
B). This insensitivity was not caused by a “high basal level of
phospho-Akt” per se, as lowering the basal level of phospho-
Akt by cotreatment with LY294002 still failed to manifest any
additional inhibitory effects (Fig. 9C).
To determine whether any other oncogenic events could in-
duce a similar insensitivity to clusterin, we transfected HEK293
cells with an empty vector or an oncogenic form of H-Ras,
H-Ras(V12). The oncogenic H-Ras(V12) protein constitu-
tively elicits downstream signaling pathways, including that of
the PI3K, independently of upstream receptor tyrosine ki-
nases. In the control HEK293 vector, clusterin almost com-
pletely blocked HeLa-CM-mediated Akt phosphorylation. In
contrast, in HEK293-Ras cells, clusterin showed only a mar-
ginal inhibitory effect (Fig. 9D). The inhibition of H-Ras pro-
tein in these cells, with a farnesyl transferase inhibitor, signif-
icantly restored their sensitivity to clusterin (see Fig. S5B in the
supplemental material). To determine if this insensitivity was
due to the uncontrolled activation of downstream IGF-1 sig-
naling or to transformed cells secreting other factors that acted
upstream of Akt, the serum-free CM from these cells were
tested for their abilities to activate Akt. Compared with HeLa
or wild-type HEK293 cells, the basal levels of phospho-Akt in
both HEK293T and HEK-Ras cells were much higher under
serum deprivation conditions. However, unlike HeLa-CM, the
CM from HEK or its transformed counterparts failed to acti-
vate Akt when tested with NB4 cells. These results suggest that
oncogenic activation downstream of IGF-1 signaling can lead
to insensitivity to clusterin-mediated control without the secre-
tion of other activating factors.
Synthesis of clusterin during serum deprivation is indepen-
dent of IGF-1 signaling. It has been reported that IGF-1 re-
ceptor signaling regulates clusterin expression (10), and we
showed that clusterin was secreted during serum deprivation
(Fig. 4E). We therefore determined if IGF-1 signaling could
affect the synthesis and/or secretion of clusterin during serum
deprivation. Clusterin undergoes several steps of posttransla-
tional modiﬁcations, including glycosylation, proteolytic cleav-
age, and disulﬁde bond formation (28, 41). The precursor and
mature (to-be-secreted) forms could be differentiated easily by
treatment with the reducing agents that disrupt the intermo-
lecular (between  and  chains) disulﬁde bonds present only
in the mature form. We analyzed the whole-cell lysates of
HeLa cells grown in serum-rich or serum-free medium in the
presence or absence of a reducing agent. Both the total and the
secreted clusterin levels were found to be elevated during se-
rum starvation (see Fig. S6A in the supplemental material),
and the time course analysis further revealed that the level of
the proteolytically processed (mature) form could be increased
within 12 h of serum deprivation (see Fig. S6B in the supple-
mental material). This initial elevation in protein level ap-
peared not to be due to its transcripts, which began to increase
24 h after serum deprivation (data not shown). It has been
reported that there are two isoforms of clusterin (nuclear and
secreted) present inside cells (41). To determine which isoform
was accumulated during serum deprivation, HeLa cells were
treated with tunicamycin, an inhibitor of N glycosylation. This
treatment revealed a nonglycosylated precursor form of clus-
terin (approximately 55 kDa) with a concomitant loss of the
62-kDa precursor form, indicating that only the secreted (or
nonnuclear) isoform was present during serum deprivation
(see Fig. S6C in the supplemental material). Next, we deter-
mine if the perturbation of IGF-1 signaling could affect the
level of clusterin during serum deprivation. The addition of
IGF-1 or IGF-1 receptor-neutralizing antibody failed to inﬂu-
ence the level of clusterin (see Fig. S6D and E in the supple-
mental material). We then determined if restimulation of
starved cells with serum or IGF-1 could affect its level. Re-
stimulation with serum led to a reduction in the clusterin level
within 2 h, but IGF-1 failed to exert any effects at later time
points and higher concentrations (see Fig. S6F in the supple-
mental material). These results showed that the synthesis of
clusterin during serum deprivation is independent of IGF-1
signaling. Reduction of the clusterin level within 2 h after
serum restimulation suggests that its level could be controlled
by protein translation and/or turnover. To test this possibility,
we treated HeLa cells grown under serum-rich or -starved
conditions with cycloheximide and examined the level of clus-
terin over a time course. Within2ho ftreatment, only a small
fraction (approximately 10%) of the precursor form was de-
tected under both serum-rich and -starved conditions. Intrigu-
ingly, while around 35% of the mature form was detected
under serum-rich conditions (see Fig. S6G in the supplemental
material), a signiﬁcant fraction (75%) of the mature form still
remained under serum-starved conditions, indicating a post-
translational regulation of clusterin.
DISCUSSION
The ability of cancer cells to modulate the cellular signaling
pathways in accordance with the changing local environment
represents one of the molecular mechanisms underlying the
progression of malignancy and resistance to anticancer drugs.
The PI3K-Akt pathway serves as a converging point for many
upstream signaling receptors. However, the cellular mecha-
nisms that modulate this pathway under growth-constraining
conditions are not clearly deﬁned. In the present study, we
show that serum-deprived cancer cells secrete a PI3K-Akt-
regulating activity that consists of both positive and negative
factors. Via biochemical puriﬁcation, we reveal that cancer
cell-derived clusterin and IGF-1 constitute this regulatory ac-
tivity. We demonstrate furthermore that clusterin negatively
modulates the PI3K-Akt pathway through inhibition of IGF-1,
a major growth factor secreted by serum-starved cancer cells,
thus identifying a novel function for clusterin.
Previous studies with clusterin, including overexpression and
knockdown in cancer cells, implicated it in different aspects of
the tumorigenic process (5, 10, 29, 41, 49). Clusterin exists in
an intracellular form and an extracellular form, and its func-
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 tional roles in biological processes have been enigmatic. Dif-
ﬁculties in delineating its function as an intracellular or an
extracellular factor may explain many of its promiscuous func-
tions. The two isoforms (nuclear and secreted) of clusterin
were shown to play opposing functions for cell survival, in
which the nuclear form was proapoptotic, and the secreted
form was prosurvival (30, 41). We conﬁrmed that during serum
deprivation in HeLa cells, only the secreted form of clusterin
could be found (see Fig. S6A to C in the supplemental mate-
rial), and its knockdown in HeLa-PH cells, in which prosurvival
IGF-1 signaling was compromised, led to apoptosis (see Fig. S7
in the supplemental material). This suggests that the secretory
forms, while they are still inside the cell, play a prosurvival
function, in agreement with other studies (41). Relatively few
studies have focused on the extracellular functions of clusterin
in relation to tumorigenesis. Nevertheless, several experimen-
tal results identiﬁed its inhibitory roles in cell proliferation (5,
45, 50), which is consistent with our ﬁnding (Fig. 6D). For
instance, it has been shown that recombinant human clusterin
suppressed epithelial cell proliferation, and a high incidence of
papilloma was found in clusterin-null mice in a chemical-in-
duced skin carcinogenesis model (45). However, the underly-
ing mechanism remains unknown. This is partly due to its
capacity to bind to a wide range of molecules, including lipids
and protein aggregates. Thus, clusterin is thought to play pro-
miscuous functions (41), often resulting in conﬂicting results
(18, 48). Despite this view, we found that the inhibitory effect
of clusterin on the PI3K-Akt pathway could be attributed to its
preferential attenuation of IGF-1, not to other growth factors
such as EGF (Fig. 7).
Cancer cells under stress conditions may secrete many au-
tocrine and/or paracrine factors that feed into the PI3K-Akt
pathway to support cell growth and survival (4, 6, 24, 36).
Surprisingly, however, we found that the inhibition of IGF-1 or
its receptor alone almost completely abolished the Akt activa-
tion induced by CM from the serum-starved cancer cells (Fig.
7B and C). We showed that, under identical serum deprivation
conditions, HeLa cells with an impaired PI3K-Akt pathway
failed to secrete the Akt-activating activity (Fig. 2D) and IGF-1
(Fig. 7), identifying a crucial role for this pathway in producing
its own upstream activator. Whether this ﬁnding can be ex-
tended to other cancer cell types and different stress conditions
needs to be determined. Nevertheless, this result further ex-
plains why the deactivation of the PI3K-Akt pathway could be
so effective in managing human cancers.
While the presence of IGF-1 in the tumor microenviron-
ment is known (37), its secretion by serum-starved cancer cells
has not been readily observed. One potential reason might be
its biological accessibility. For example, we showed that, as
measured by ELISA, the levels of IGF-1 in serum-free CM
were marginal, especially at later time points (i.e., 72 h com-
pared to 36 h). However, as revealed by ELISA following heat
treatment, this was not due to a lack of its secretion (Fig. 7D).
Instead, this result demonstrates that a large portion of se-
creted IGF-1 exists in a nonaccessible complex, indicating an
important role for extracellular factors in modulating the bio-
availability of IGF-1 (37). The current study identiﬁes a novel
role for cancer cell-derived clusterin in this process.
Extracellular clusterin manifests a growth suppressive func-
tion (Fig. 6D). Why would tumor cells secrete a factor that
could potentially suppress their own growth? The level of clus-
terin is tightly associated with various cellular stress responses
(7, 41). Therefore, its secretion may reﬂect the cellular adap-
tive responses to endure adverse environmental conditions
(i.e., by suppressing its own growth and that of surrounding
cells). In a mouse model of prostate cancer, it has been shown
that epithelial cancer cells initiate and promote the clonal
expansion of stromal ﬁbroblasts that lack the p53 tumor sup-
pressor gene (23), indicating that the cancer cell-derived fac-
tors initially impose selective pressures (i.e., antiproliferation)
on neighboring cells. The presence of clusterin in the tumor
microenvironment can contribute to such selective pressures.
For example, the availability of glucose is often limited in the
tumor microenvironment (16), and its uptake, a process medi-
ated by the PI3K-Akt pathway (13, 22), can be a deciding
factor for cell proliferation. Under this condition, those cells
with a higher resistance (or insensitivity) to clusterin would
gain growth advantages and thus would be positively selected.
Our demonstration that constitutive activation of oncogenic
signaling led to insensitivity to clusterin is consistent with this
idea (Fig. 9).
The cellular adaptive response to environmental stresses is
recognized as an important mechanism that facilitates tumor-
igenic progression (20, 43). We identiﬁed an extracellular reg-
ulatory system for the PI3K-Akt pathway in cancer cells under
serum deprivation stress. We demonstrated that cancer cell-
derived clusterin, an extracellular stress protein, and IGF-1
constituted this regulatory system, thus providing a genetic tool
with which to better understand the complex signaling inter-
plays between cancer cells and their environment.
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by a neutralizing antibody. The purified IGF-1 (1 ng / ml in 
serum free medium) or fetal bovine serum (1 % in serum free 
medium) was pre-incubated with the control (monoclonal anti-
Actinin) or IGF-1 neutralizing antibody (4 µg /ml) for 30 
minutes on ice. The Akt activating activity of each medium was 
assayed in NB4 cells. D) The serum-starved HeLa cells were 
incubated with the untreated or heat-treated HeLa-CM and 
the cell lysates were immumoprecipiated with EGF or IGF-
1 β receptor antibody.  The immunoprecipitates were 
analyzed by phosphotyrosine antibody.  An aliquot of the 
lysate was also analyzed for phospho-Akt.  The 
representative result of at least three independent 
experiments was shown.  E) The serum-starved HeLa cells 
were stimulated with different amounts of purified EGF, 
analyzed for activation of EGF receptor, Akt, and Erk.  
 c
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Supplementary FIG.  4.  A) The indicated amount of purified IGF-1 was analyzed by Western 
blot with a monoclonal IGF-1 antibody (CBL52, Chemicon International).  B) HEK293T-
CM transfected with the control, the V5-6 x His tagged human or zebrafish Clusterin 
vector was analyzed by Western blot with a monoclonal human Clustern antibody or 
monoclonal V5 antibody (Invitrogen).  C) The amino acid sequence alignment of human 
and zebrafish Clusterin.  The letters in red indicate the identical amino acid.  HEK293-PH-EGFP HEK293T-PH-EGFP HEK293T-PH-EGFP (+LY)
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Supplementary FIG.  5.  A) The PH-EGFP construct was transfected into HEK293 or 
HEK293T cells grown in serum rich medium.  Cells were treated with LY294002 (20 
µM) for 90 minutes before fixation and imaging.  B) HEK293-Ras cells grown in serum rich 
medium with or without farnesyltransferase inhibitor (125 ng / ml for 36 hrs) were serum-starved 
for 30 min, then treated with HeLa-CM mixed (1:1) with the control (Con) or Clusterin (Clu) 
containing HEK293T-CM. The level of phospho-Akt was analyzed. The phospho-Erk level was 
measured to confirm the inhibition of Ras function by farnesyltransferase inhibitor.    +    -    +    +    -     -    β-ME   
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Supplementary FIG.  6.  A) The conditioned medium and the whole cell lysates of HeLa cells 
grown in serum rich medium or serum-starved for overnight were treated with or without β-
mercaptoethanol (β-ME) prior to SDS-PAGE.  The resolved proteins were analyzed for Clusterin.  
Schematic representation of precursor and mature forms of Clusterin is shown on the right. B) 
The whole cell lysates of HeLa cells grown in serum free medium for the indicated time were 
analyzed for Clusterin.  C) The whole cell lysate of HeLa cells grown in serum rich or 
serum free condition with the indicated amount of tunicamysin (an inhibitor of N-
glycosylation) was analysed with the polyclonal or monoclonal Clusterin antibody. -    +     -      +     -     +    IGF (5 ng/ml)
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Supplementary FIG.  6.  D) HeLa cells were serum starved for the indicated time in the 
presence or absence with IGF-1, the whole cell lysate was analyzed for Clusterin. E) The 
conditioned medium and  whole cell lysates of HeLa cells serum-starved in the presence of 
indicated reagents were analyzed for Clusterin.  F) The serum-starved HeLa cells were re-
stimulated with serum or IGF-1 for the indicated time, and the whole cell lysates were analyzed 
for Clusterin.  G) HeLa cells grown in serum rich or serum free condition was treated with 
cycloheximide (25 µg/ml) for the indicate time, and the whole cell lysates were analyzed for 
Clusterin, p85 subunit of PI3K, and IGF-1 receptor.  28kD
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Supplementary FIG.  7.  HeLa-PH cells were transfected with the indicated amount of 
Clusterin shRNA vector, the whole cell lysate of serum starved (12 hr) cells were 
analyzed for Clusterin. The same blot was analyzed for PARP and Caspase-3 to check for 
apoptosis.  
 